BioCryst Pharmaceuticals Valuation

BCRX Stock  USD 5.15  0.14  2.79%   
At this time, the firm appears to be undervalued. BioCryst Pharmaceuticals shows a prevailing Real Value of $7.46 per share. The current price of the firm is $5.15. Our model approximates the value of BioCryst Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 1.47 B, profit margin of (0.68) %, and Return On Equity of -19.25 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Price Book
56.5858
Enterprise Value
1.5 B
Enterprise Value Ebitda
(12.63)
Price Sales
3.2035
Enterprise Value Revenue
4.4325
Undervalued
Today
5.15
Please note that BioCryst Pharmaceuticals' price fluctuation is moderately volatile at this time. Calculation of the real value of BioCryst Pharmaceuticals is based on 3 months time horizon. Increasing BioCryst Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for BioCryst Pharmaceuticals is useful when determining the fair value of the BioCryst stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of BioCryst Pharmaceuticals. Since BioCryst Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioCryst Stock. However, BioCryst Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  5.15 Real  7.46 Target  15.2 Hype  5.14 Naive  5.75
The real value of BioCryst Stock, also known as its intrinsic value, is the underlying worth of BioCryst Pharmaceuticals Company, which is reflected in its stock price. It is based on BioCryst Pharmaceuticals' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of BioCryst Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence BioCryst Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
7.46
Real Value
12.53
Upside
Estimating the potential upside or downside of BioCryst Pharmaceuticals helps investors to forecast how BioCryst stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioCryst Pharmaceuticals more accurately as focusing exclusively on BioCryst Pharmaceuticals' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-0.28-0.21-0.14
Details
Hype
Prediction
LowEstimatedHigh
0.075.1410.21
Details
Naive
Forecast
LowNext ValueHigh
0.695.7510.82
Details
11 Analysts
Consensus
LowTarget PriceHigh
13.8315.2016.87
Details

BioCryst Pharmaceuticals Investments

(24.52 Million)

BioCryst Pharmaceuticals Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining BioCryst Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare BioCryst Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioCryst Pharmaceuticals competition to find correlations between indicators driving BioCryst Pharmaceuticals's intrinsic value. More Info.
BioCryst Pharmaceuticals is number one stock in net asset category among related companies. It is number one stock in price to book category among related companies . The ratio of Net Asset to Price To Book for BioCryst Pharmaceuticals is about  9,135,861 . Price To Book Ratio is likely to rise to -2.4 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value BioCryst Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioCryst Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioCryst Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioCryst Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioCryst Pharmaceuticals and how it compares across the competition.

About BioCryst Pharmaceuticals Valuation

The stock valuation mechanism determines the current worth of BioCryst Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of BioCryst Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of BioCryst Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing BioCryst Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of BioCryst Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioCryst Pharmaceuticals. We calculate exposure to BioCryst Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to BioCryst Pharmaceuticals's related companies.
Last ReportedProjected for 2024
Gross Profit325.1 M341.4 M
Pretax Profit Margin(0.68)(0.72)
Operating Profit Margin(0.31)(0.33)
Net Loss(0.68)(0.72)
Gross Profit Margin 0.98  1.03 

8 Steps to conduct BioCryst Pharmaceuticals' Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioCryst Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioCryst Pharmaceuticals' valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain BioCryst Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine BioCryst Pharmaceuticals' revenue streams: Identify BioCryst Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research BioCryst Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
  • Establish BioCryst Pharmaceuticals' growth potential: Evaluate BioCryst Pharmaceuticals' management, business model, and growth potential.
  • Determine BioCryst Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioCryst Pharmaceuticals' estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

BioCryst Pharmaceuticals Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as BioCryst Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding192.2 M

BioCryst Pharmaceuticals Current Valuation Indicators

Valuation refers to the process of determining the present value of BioCryst Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value BioCryst we look at many different elements of the entity such as BioCryst's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. BioCryst Pharmaceuticals' valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final BioCryst Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as BioCryst Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use BioCryst Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes BioCryst Pharmaceuticals' worth.
When determining whether BioCryst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioCryst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocryst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocryst Pharmaceuticals Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for BioCryst Stock analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.18)
Revenue Per Share
1.724
Quarterly Revenue Growth
0.174
Return On Assets
(0.12)
Return On Equity
(19.25)
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.